ArticleBMC cancer2026
Recombinant zoster vaccine uptake and series completion among immunocompromised adults with cancer in the US.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo estimate recombinant zoster vaccine (RZV) use among adults with cancer since the 2021 US Advisory Committee on Immunization Practices (ACIP) recommendation to vaccinate immunocompromised adults aged ≥ 19 years and gather insights into oncologist practices, perceptions, barriers, and facilitators to RZV vaccination among adults with cancer.
methodsIn this retrospective cohort study, RZV uptake (≥ 1 dose) and completion (2 doses) were assessed among RZV-naïve, immunocompromised patients aged ≥ 19 years with a solid tumor cancer or hematologic malignancy using IQVIA's open medical and prescription claims. Patients were followed from the ACIP voting date (October 20, 2021) until June 30, 2023. RZV uptake, series completion, time to completion, and dosing schedule compliance were described. Generalized estimation equation models assessed factors associated with uptake. Fifteen oncologists were interviewed regarding their RZV practices, perceptions, barriers, and facilitators, and themes were generated based on responses.
resultsAmong 388,923 and 277,314 RZV-naïve patients with a solid tumor cancer or hematologic malignancy, cumulative RZV uptake increased gradually, reaching 7.6% and 8.6%, respectively. Series completion rates at 6 and 12 months among those who initiated RZV were 63.2% and 70.9% in the solid tumor cancer cohort and 64.7% and 71.6% in the hematologic malignancy cohort. The odds of RZV uptake varied by cancer type and tended to increase with age and household income. Oncologists reported that they primarily serve an advisory role in vaccination due to workflow and financial challenges and competing patient needs, opting instead to delegate this responsibility to primary care providers and pharmacists.
conclusionRZV uptake among RZV-naïve immunocompromised patients with cancers has been slow and suboptimal since the 2021 ACIP recommendation, but series completion is likely once initiated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.